日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar

影响参考利妥昔单抗和利妥昔单抗生物类似药PF-05280586给药后输注相关反应的因素

Courville, Jocelyn; Nastoupil, Loretta; Kaila, Nitin; Kelton, John; Zhang, Jeffrey; Alcasid, Ann; Nava-Parada, Pilar

The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars

利妥昔单抗在慢性淋巴细胞白血病治疗中的作用及生物类似药的潜在应用价值

Brown, Jennifer R; Cymbalista, Florence; Sharman, Jeff; Jacobs, Ira; Nava-Parada, Pilar; Mato, Anthony

Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

CC-292(一种高选择性布鲁顿酪氨酸激酶抑制剂)单药治疗复发/难治性慢性淋巴细胞白血病的I期研究

Brown, Jennifer R; Harb, Wael A; Hill, Brian T; Gabrilove, Janice; Sharman, Jeff P; Schreeder, Marshall T; Barr, Paul M; Foran, James M; Miller, Thomas P; Burger, Jan A; Kelly, Kevin R; Mahadevan, Daruka; Ma, Shuo; Li, Yan; Pierce, Daniel W; Barnett, Evelyn; Marine, Jeffrey; Miranda, Monika; Azaryan, Ada; Yu, Xujie; Nava-Parada, Pilar; Mei, Jay; Kipps, Thomas J

Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors

采用 Toll 样受体激动剂给药的肽疫苗可有效治疗和预防自发性乳腺肿瘤

Pilar Nava-Parada, Guido Forni, Keith L Knutson, Larry R Pease, Esteban Celis